For patient 6, no targeted treatment has been employed so far, as sirolimus was started a year prior to the diagnosis of STAT3-GOF and led to satisfactory control of autoimmune pancytopenia and lymphadenopathy. This evidence concerns the gene STAT3 and Pancytopenia.